Dyadic signs development, commercial license deal with European biotech for precision-fermented dairy proteins
DYAI•Development and commercial license agreement
Dyadic said it signed a development and commercial license agreement with a European biotechnology company to add precision-fermented dairy proteins to its pipeline.
The deal structure includes potential development payments, commercial milestone-style payments, licensing revenue, and other economic participation tied to commercialization.
The program will move into strain optimization, process development, and commercial scale-up using Dyadic’s Dapibus precision-fermentation platform.
